The study found that people with any type of COVID-19 infection were twice as likely to have a major cardiac event, such as heart attack, stroke or even death, for up to three years after diagnosis. Stanley Hazen, MD, PhD summarizes the findings of this Cleveland Clinic led trial and implications for practice and future research.

Learn more about C5 Research at Cleveland Clinic
https://my.clevelandclinic.org/research/c5research

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162.

Eric Roselli, MD, provides an overview, a complex cardiac sarcoma case is presented by Holliann Willekes, MD, followed by an update on imaging modalities from Patrick Collier, MD, PhD, and a perspective on pathology from Marc Halushka, MD, PhD.  Learn more about Tall Rounds online. http://2207941.mediaspace.kaltura.com/category/Tall+Rounds/75663251

Lee Kirksey, MD, moderates a panel discussion on diversity in medicine with Miriam Jacob, MD, Milind Desai, MD, James Carter, MD, and Quinn Capers, MD, Visiting Professor from Howard University.

A Cleveland Clinic-led trial found that a minimally-invasive procedure – left atrial appendage closure (LAAC) – resulted in significantly less bleeding in patients undergoing a catheter ablation to treat atrial fibrillation, compared to oral anticoagulation, while preserving low rates of stroke, blood clots and death. The OPTION Trial was presented at the American Heart Association’s Scientific Sessions 2024. Walid Saliba, MD speaks with Oussama Wazni, MD, Section Head of Cardiac Electrophysiology and Pacing at Cleveland Clinic and Primary Investigator of the OPTION Trial, about the results of the trial and implications for practice.

Learn more about the Atrial Fibrillation Stroke Prevention Center
https://my.clevelandclinic.org/departments/heart/depts/atrial-fibrillation-stroke-prevention-center

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM).  An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging.


Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Clinicians should consider statin therapy for primary prevention. Vikas Sunder, MD, a cardiologist in Preventive Cardiology, reviews indicators and considerations for statin initiation as well as barriers to adherence.

Learn more about the Section of Preventive Cardiology and Rehabilitation
https://my.clevelandclinic.org/departments/heart/depts/preventive-cardiology-rehabilitation

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

Roy Chung, MD sits down with Thomas Callahan, MD to talk about the challenges of left bundle branch area pacing, particularly management after implant. Dr. Chung has much experience with conduction system pacing and shares his experience during this podcast.

Learn more about Cleveland Clinic's Pacemaker and Defibrillator Lead Extraction Center
https://my.clevelandclinic.org/departments/heart/depts/pacemaker-defibrillator

Interested in learning more about lead management? Join experts in the field at LEADconnection.
https://leadconnection.org/

Amanda Vest, MBBS, discusses metabolic challenges in heart failure, new opportunities with obesity and cachexia. Learn more about Cleveland Clinic's Center for Heart Failure Treatment and Recovery.

Patients with hypertrophic obstructive cardiomyopathy can suffer from arrhythmias before and after septal myectomy. Dr. Nicholas Smedira specializes in the surgical management of LVOT obstruction and discusses the impact of left ventricular outflow obstruction on the heart's conduction system.

Learn more about the Hypertrophic Cardiomyopathy Center
https://my.clevelandclinic.org/departments/heart/depts/hypertrophic-cardiomyopathy

In this episode, Amar Krishnaswamy, MD, leads a discussion on the role of percutaneous mitral valve therapies in 2024. Learn more about Cleveland Clinic's Mitral and Tricuspid Valve Center: https://my.clevelandclinic.org/departments/heart/depts/mitral-and-tricuspid-valve-center